# OnCo record lung-adenocarcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/lung-adenocarcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "lung-adenocarcinoma" ;
  schema:name "Adenocarcinoma of the lung"@en ;
  schema:alternateName "Lung adenocarcinoma"@en, "Pulmonary adenocarcinoma"@en, "Adenocarcinoma"@en, "Adenocarcinoma (~50%)"@en, "Non-squamous non-small-cell lung cancer (in trial entry criteria)"@en, "Bronchioloalveolar carcinoma (term retired in 2011)"@en ;
  schema:description "Lung adenocarcinoma is the most common type of lung cancer and the form that non-smokers usually get; it starts in the mucus-making gland cells of the small airways, most often at the edge of the lung. It is the type in which testing for a driver mutation matters most, because half of cases have one that a tablet can target."@en ;
  schema:url <https://onco.cc/cancers/lung-adenocarcinoma/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Adenocarcinoma_of_the_lung> ;
  schema:citation <https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types/types>, <https://doi.org/10.1016/j.jtho.2021.11.003>, <https://doi.org/10.1097/jto.0b013e318206a221>, <https://doi.org/10.1056/nejmoa1801005> ;
  onco:tag "subtype-page", "wave4", "lung" ;
  onco:related <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-squamous-cell-carcinoma/>, <https://onco.cc/cancers/large-cell-lung-carcinoma/>, <https://onco.cc/cancers/invasive-mucinous-adenocarcinoma-lung/>, <https://onco.cc/cancers/lung-adenocarcinoma-in-situ-and-minimally-invasive/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/trop2/> ;
  onco:drugs <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nintedanib/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:trials <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/trials/keynote-042/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/cancers/pdl1-high-nsclc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/>, <https://onco.cc/cancers/kras-g12c-nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/>, <https://onco.cc/cancers/resectable-nsclc/>, <https://onco.cc/cancers/stage-iii-unresectable-nsclc/>, <https://onco.cc/terms/lobectomy/> .